Single-use systems (SUS) have revolutionized biopharmaceutical manufacturing, with single-use bioreactors (SUBs) leading the charge in recent decades. However, while the adoption of SUBs has plateaued, other forms of single-use technology (SUT) are gaining momentum. The landscape is evolving
Medical imaging has undergone significant transformations over the years, and artificial intelligence (AI) has emerged rapidly as a game-changer in this field. Traditionally, medical imaging techniques like X-rays, MRI, and CT scans have been vital for diagnosing various conditions. However, with
The biotech landscape is abuzz with the launch of Red Queen Therapeutics, a startup that aims to revolutionize antiviral treatments. Backed by a $55 million investment from venture firm Apple Tree Partners and additional funding from the Biomedical Advanced Research and Development Authority
The biotech industry has seen a flurry of activity, with companies undertaking significant workforce restructuring, achieving crucial FDA approvals, and navigating the complex landscape of clinical trials. These developments reflect both the challenges and advancements within the sector, offering a
The FDA's recent approval of a new treatment for severe alopecia areata marks a significant advance in addressing this challenging condition. Deuruxolitinib, branded as Leqselvi and developed by Sun Pharmaceutical Industries, will now compete with existing treatments from Eli Lilly and Pfizer,
Artiva Biotherapeutics has made headlines with its successful initial public offering (IPO), raising an impressive $167 million. This significant milestone not only highlights Artiva's strategic pivot toward autoimmune disease treatments using donor-derived cell therapies but also marks a
HilleVax, a biotechnological firm previously in the spotlight for its experimental Norovirus vaccine, HIL-214, has made headlines again. After an extensive and ultimately disappointing Phase 2b trial in infants, the company is now strategizing a new target demographic: adults. Given the intricate
Despite tremendous advancements in medical science, drug discovery remains a daunting challenge, particularly when it comes to illnesses involving complex protein interactions. Conventional drug development strategies fall short when faced with the vast network of protein-protein interactions
As we witness a demanding push for the development of innovative asthma treatments, over 80 key companies globally have embarked on an ambitious journey. This initiative aims to create a robust arsenal of more than 90 therapeutic approaches, targeting a condition that continues to affect the
The partnership between Tetra Pharm Technologies and Kvantify signifies a major step forward in the realm of drug discovery, particularly within the arena of the endocannabinoid system (ECS). This alliance is poised to not only speed up the discovery process but also holds the promise of yielding
